Researchers are exploring the potential of lithium, a medication commonly prescribed for bipolar disorder and depression, as a treatment for dementia. The neurological condition, which affects 982,000 people in the UK, currently has no cure or preventative treatment.
Previous studies have indicated a link between lithium deficiency and cognitive impairment. Research published in the journal Nature found lower levels of lithium in the brains of individuals diagnosed with Alzheimer's disease. In animal models, lithium deficiency has been observed to accelerate cognitive decline and the buildup of brain plaque, both characteristic of Alzheimer's.
In mice genetically engineered to develop Alzheimer's, treatment with low-dose lithium reportedly improved memory performance and reduced indicators of brain damage. Scientists hypothesize that lithium may protect brain cells crucial for memory and cognition, while also preserving neural connections.
These latest findings were detailed in a perspective article in Translational Psychiatry, where researchers advocated for further investigation into low-dose lithium as a potential therapeutic option for individuals in the early stages of Alzheimer's disease.
However, experts caution that the research is still in its early stages. Dr. Richard Oakley, associate director of research and innovation at Alzheimer's Society, noted that while the study contributes to the ongoing discussion about lithium's potential role in Alzheimer's, it does not demonstrate that the medication can prevent or treat the disease. He emphasized that current clinical trials in early-stage Alzheimer's patients have been small, and there is no definitive evidence of its impact. Oakley concluded that exploring all promising avenues through further research is essential to identify treatments that can make a meaningful difference for those affected by dementia.